Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002012383-25-002600
Filing Date
2025-10-17
Accepted
2025-10-17 18:13:44
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5666
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2796
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 481
  Complete submission text file 0002012383-25-002600.txt   10796
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Subject) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94231 | Film No.: 251401854
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)